Depressive symptoms in acute schizophrenia

doi:10.1016/0364-7722(79)90058-4

Progress in Neuro-Psychopharmacology

Volume 3, Issue 4, 1979, Pages 429-433

Progress in Neuro-Ps...

https://doi.org/10.1016/0364-7722(79)90058-4 Get rights and content

Abstract

1.
1. The incidence of psychopathological symptoms rated by the CPRS was compared in 54 English depressed patients and 52 Swedish depressed patients.
2.
2. A new rating scale for depression was created from the 10 items shown to be most sensitive to treatment change. The Montgomery and Åsberg Depression Rating Scale (MADRS) was found to be more sensitive to treatment change than the Hamilton Rating Scale (HRS).
3.
3. The incidence of psychopathological symptoms was assessed using the full Comprehensive Psychopathological Rating Scale (CPRS) in 50 patients with unequivocal acute schizophrenia. 36 patients were rated again after treatment and a 12 item rating scale for schizophrenia was derived from the items best able to discriminate between responders and non responders.
4.
4. The schizophrenia scale was found to be a more sensitive discriminator between responders and non responders than the Brief Psychiatric Rating Scale (BPRS) in the 25 patients rated on both scales simultaneously.
5.
5. There was a relatively high incidence of depressive symptoms rated on the MADRS in acute schizophrenia suggesting that depressive symptoms are a commoner presenting feature of acute unequivocal schizophrenia than is normally acknowledged.

References (10)

S.A. Montgomery et al.
Development of a schizophrenia scale sensitive to change
Neuropharmacology
(1978)
M. Åsberg et al.
The Comprehensive Psychopathological Rating Scale
Acta Psychiat. Scand. Suppl.
(1978)
J.P. Feighner et al.
Diagnostic criteria for use in psychiatric research
Arch. Gen. Psychiat.
(1972)
M. Hamilton
Development of a rating scale for primary depressive illness
Brit. J. Soc. Clin. Psychol.
(1967)
S. Montgomery et al.
A new depression scale designed to be sensitive to change
Brit. J. Psychiat.
(1979)

There are more references available in the full text version of this article.

Cited by (50)

A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy
2022, Asian Journal of Psychiatry
Tobacco smoking and nicotine dependence in first episode and established psychosis
2019, Asian Journal of Psychiatry
People with psychotic disorders have increased premature mortality in comparison with the general population, with high rates of cigarette use a contributing factor. We aimed to describe the prevalence of cigarette use and nicotine dependence (ND) in first episode psychosis (FEP), and established psychosis; and to investigate associations between clinical symptoms and ND.
Smoking and clinical data were collected from two cohorts: 181 people with FEP recruited as part of the Physical Health and Substance Use Measures in First Onset Psychosis (PUMP) study and from 432 people with established psychosis recruited as part of the Improving physical health and reducing substance use in psychosis randomised controlled trial (IMPaCT RCT).
The prevalence of cigarette smoking was 78% in FEP and 62% in established psychosis. Forty nine percent (n = 60) of smokers in the FEP cohort and 69% (n = 183) of smokers with established psychosis were highly nicotine dependent. Being a highly nicotine dependent smoker was significantly associated with higher PANSS positive symptom scores (F = 5.480 p = 0.004), and with decreased scores on the Rosenberg self-esteem scale (F = 3.261, p = 0.039) in established psychosis. There was no diagnostic specificity identified in relation to smoking or ND in both groups.
High rates of cigarette usage and nicotine dependence are problems from the early stages of psychosis. ND is higher in people with established psychosis. Smoking cessation strategies as part of comprehensive management of psychotic disorders at every stage require further development and evaluation.
Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the “self-medication” hypothesis in schizophrenia
2018, Schizophrenia Research
One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more than the general population to “self-medicate” cognitive deficits and other symptoms. This study tested the self-medication hypothesis by examining the effects of smoking abstinence and resumption on cognition in patients with schizophrenia. Nicotine-dependent smokers with schizophrenia (n = 26) were trained on a cognitive battery and then hospitalized to achieve and maintain confirmed abstinence from smoking for ~ 1 week. Cognition was tested while smoking as usual (baseline), one day after smoking cessation (early abstinence), ~ 1 week later (extended abstinence), and within ~ 3 weeks of resuming smoking (resumption). The test battery included measures of processing speed, attention, conflict resolution, verbal memory, working memory, verbal fluency, and executive function to evaluate multiple cognitive domains affected by schizophrenia. Positive and negative symptoms of schizophrenia, depressive symptoms, and dyskinesia were also measured at baseline and after prolonged abstinence. There were no significant changes in global cognitive test performance with smoking cessation, abstinence, or resumption. There were small decreases in a measure of processing speed and delayed verbal recall with abstinence, but these findings failed to survive adjustments for multiple comparisons. Surprisingly, in this within subject “On-Off-Off-On” design, there were no significant effects of early or prolonged abstinence from smoking on cognitive and behavioral measures in smokers with schizophrenia. The results of this study challenge the widely held “self-medication” hypothesis of smoking and schizophrenia, question the extent of pro-cognitive effects of smoking and nicotine in schizophrenia, and support encouraging smoking cessation in schizophrenia.
L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry
2017, Journal of Affective Disorders
Citation Excerpt :
Clinician and patient-rated study measures were collected at every visit. Depressive symptoms were assessed with the Montgomery Asberg Depression Rating Scale (MADRS) (Montgomery, 1979) and manic symptoms with the Young Mania Rating Scale (YMRS) (Young et al., 1978). Clinical Global Impressions - Bipolar Severity (CGI-BP-S) (Spearing et al., 1997) was administered to integrate symptoms and burden.
L-methylfolate is a compelling candidate to treat bipolar I major depressive episodes. While approved as an adjunct for unipolar major depressive disorder, no studies have been done to assess the tolerability, safety, and efficacy of L-methylfolate for bipolar depression. As a first step, we developed a registry of bipolar patients treated with L-methylfolate to examine tolerability and outcomes.
Subjects (N=10) received treatment as usual plus daily L-methylfolate 15 mg for 6 weeks in this open-label registry. Depressive symptoms were assessed with the Montgomery Asberg Depression Rating Scale (MADRS) and manic symptoms with the Young Mania Rating Scale (YMRS). Effect size was measured with Cohen's d to provide an estimate of potential efficacy.
The pre-treatment mean (SD) MADRS score was 23.4 (4.34); the post-treatment score was 13.9 (8.24). Cohen's d was 1.19. At post-treatment, 6/10 patients had at least 50% MADRS improvement, and 4/10 patients exhibited remission with MADRS≤10. The pre-treatment YMRS score was 3.2 (3.0); the post-treatment score was 2.7 (5.2). Cohen's d was 0.17.
This registry was a small open-label clinical trial for a fluctuating disorder. We cannot rule out that our results are due to regression to the mean. A controlled trial is warranted.
This first proof-of-concept open registry suggests that L-methylfolate in combination with treatment as usual has potential to treat bipolar depression.
Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar i disorder
2016, Journal of Affective Disorders
Citation Excerpt :
CGI-BP-S is a single-item clinician-rated scale with a possible score ranging from 1 to 7, with higher scores indicative of more severe illness (Guy, 1976a; Spearing et al., 1997). The Positive and Negative Symptom Scale (PANSS) was administered on days 7, 14, and 21, and the Montgomery–Åsberg Depression Rating Scale (MADRS) was administered on days 7 and 21 (Kay et al., 1987; Montgomery, 1979). PANSS is a 30-item clinician-rated instrument; decreases from baseline in PANSS scores are indicative of an improvement in symptoms.
Asenapine is an atypical antipsychotic for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The recommended asenapine starting dose is 10 mg bid with the option to reduce the dose to 5 mg bid if needed due to adverse effects/tolerability.
Phase IIIb, international, double-blind, fixed-dose, parallel-group, 3-week placebo-controlled trial of asenapine 5 and 10 mg bid in adults with an acute bipolar I disorder manic or mixed episode. Primary outcome was difference in asenapine versus placebo in mean change from baseline to day 21 in the Young-Mania Rating Scale (YMRS) total score. Others included difference in asenapine versus placebo in the Clinical Global Impression Scale for Bipolar Severity (CGI-BP-S) and rate of YMRS responders.
Both asenapine doses were statistically superior to placebo in mean change from baseline to day 21 in YMRS total score (−10.9, −14.4, and −14.9 for placebo, asenapine 5 mg bid, 10 mg bid, respectively). Both asenapine doses had statistically superior improvement in mean change in CGI-BP-S score at day 21. Neither asenapine dose had significantly more YMRS responders at day 21 than placebo.
Results may not be generalizable to the entire population with bipolar I disorder owing to strict inclusion criteria.
This study evaluated, by a fixed-dose design, the efficacy and safety of asenapine versus placebo in patients with bipolar I disorder. Both asenapine 5 and 10 mg bid were efficacious in treating mania associated with bipolar I disorder and were generally well tolerated.
Is good insight associated with depression among patients with schizophrenia? Systematic review and meta-analysis
2015, Schizophrenia Research
Among patients with schizophrenia, better insight may be associated with depression, but the findings on this issue are mixed. We examined the association between insight and depression in schizophrenia by conducting a systematic review and meta-analysis. The meta-analysis was based on 59 correlational studies and showed that global clinical insight was associated weakly, but significantly with depression (effect size r = 0.14), as were the insight into the mental disorder (r = 0.14), insight into symptoms (r = 0.14), and symptoms' attributions (r = 0.17). Conversely, neither insight into the social consequences of the disorder nor into the need for treatment was associated with symptoms of depression. Better cognitive insight was significantly associated with higher levels of depression. The exploratory meta-regression showed that methodological factors (e.g. the instrument used to assess depression and the phase of the illness) can significantly influence the magnitude of the association between insight and depression. Moreover, results from longitudinal studies suggest that the relation between insight and depression might be stronger than what is observed at the cross-sectional level. Finally, internalized stigma, illness perception, recovery attitudes, ruminative style, and premorbid adjustment seem to be relevant moderators and/or mediators of the association between insight and depression. In conclusion, literature indicates that among patients with schizophrenia, better insight is associated with higher levels of depressive symptoms. Thus, interventions aimed at promoting patients' insight should take into account the clinical implications of these findings.

View all citing articles on Scopus

View full text

Special topic: Recent developments in psychiatric ratingDepressive symptoms in acute schizophrenia

Abstract

Neuropharmacology

The Comprehensive Psychopathological Rating Scale

Acta Psychiat. Scand. Suppl.

Diagnostic criteria for use in psychiatric research

Arch. Gen. Psychiat.

Development of a rating scale for primary depressive illness

Brit. J. Soc. Clin. Psychol.

A new depression scale designed to be sensitive to change

Brit. J. Psychiat.

Special topic: Recent developments in psychiatric rating
Depressive symptoms in acute schizophrenia